# Evgen Pharma PLC Final Patient Recruited in STEM Phase IIa Trial

- Link: https://www.directorstalkinterviews.com/evgen-pharma-plc-final-patient-recruited-stem-phase-iia-trial/412755336
- Published: 2018-07-25T07:17:42+01:00
- Author: Giles Arbor

**Evgen Pharma plc** (LON:EVG), a clinical stage drug development company focused
on the treatment of cancer and neurological conditions, announced today that it 
has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic
breast cancer.

STEM is an open label trial that had regulatory approval to recruit 60 patients.
Following the favourable interim read-out, announced on 11 June 2018, the Principal
Investigator and the Company’s medical adviser believe there is sufficient evidence
to conclude that the main aims of the trial, being a favourable safety and tolerability
profile and evidence of clinical benefit, have been successfully met. On this basis,
the Company has decided that there is no merit in recruiting the full number of 
patients allowed under the protocol.

As at 24 July 2018, 50 patients had been enrolled in the trial. Any eligible patients
currently in screening will also be admitted to the trial.

All eligible patients will continue as per the trial protocol, and will receive 
SFX-01 until such point as they show clinical progression or reach the end of the
trial at 6 months. If they receive clinical benefit for the full duration of the
trial, like all other patients in the trial, they will be eligible for entry into
the compassionate use programme. On this basis, the final readout will occur around
the end of the calendar year; this will include details of the safety, tolerability
and the clinical benefit rate observed across all patients.

> **Dr Sacha Howell, Principal Investigator and Senior Lecturer and Honorary Consultant
> in Medical Oncology at the Christie NHS Foundation Trust, said:** “The STEM trial
> is an exploratory trial that was designed to demonstrate safety and tolerability
> with long-term exposure to SFX-01 and to provide evidence that it has anti-tumour
> activity after failure of at least one and up to three prior hormone therapies.
> With these objectives in mind, we have sufficient evidence to believe that SFX-
> 01 warrants further investigation through the conduct of a randomised placebo-
> controlled trial.”
> **Dr Stephen Franklin, CEO of Evgen Pharma PLC, commented:** “We are excited that,
> so far, the data from our exploratory STEM trial supports further clinical evaluation
> of SFX-01 and we look forward to the final read-out around the end of the calendar
> year. The next step is likely to be a placebo-controlled trial, testing SFX-01
> in combination with second-line hormone therapy in patients that have failed on
> CDK4/6 inhibitors. This is the initial setting for which we wish to see SFX-01
> approved in metastatic breast cancer.”

Share on:
